Ernexa director gets 5,943 and 5,083 options

Q: What equity awards did Peter Cicala receive from ERNA on August 31, 2026?

On August 31, 2026, Peter Cicala received two stock option grants from Ernexa Therapeutics Inc.: one for 5,943 options and another for 5,083 options, each to purchase common stock at an exercise price of $4.57 per share, expiring August 31, 2036.

Q: What are the vesting terms for the 5,943 ERNA stock options granted to Peter Cicala?

For the 5,943 Ernexa Therapeutics Inc. options, one-third of the underlying shares vest on the first anniversary of the August 31, 2026 grant date. The remaining shares vest in 24 substantially equal monthly installments, subject to continued service.

Q: How do the 5,083 ERNA stock options granted to Peter Cicala vest?

The 5,083 Ernexa Therapeutics Inc. stock options, issued in lieu of prorated 2026 director cash compensation under the Director's Compensation Plan, vest 100% on December 31, 2026, subject to continued service.

Q: Were Peter Cicala’s 5,083 ERNA stock options part of his cash compensation?

Yes. The 5,083 options were granted in lieu of prorated director's cash compensation for 2026 under the Director's Compensation Plan effective August 15, 2026, and were granted under Ernexa Therapeutics Inc.'s 2026 Omnibus Equity Incentive Plan.

Director Peter Cicala was granted 11,026 ERNA stock options at $4.57, vesting partly over time and fully by Dec. 31, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Ernexa Therapeutics Inc. (ERNA) reported that director Peter Cicala received two grants of stock options on August 31, 2026. One grant covers 5,943 options with an exercise price of $4.57 per share, vesting one-third on the first anniversary and the rest in 24 monthly installments, expiring August 31, 2036. A second grant covers 5,083 options at $4.57 per share, issued in lieu of prorated 2026 director cash compensation under the Director's Compensation Plan, vesting 100% on December 31, 2026, also expiring August 31, 2036.

Insider Trade Summary

Grant/Award: 11,026 shares

Grant/Award 2 txns

Insider Cicala Peter

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to buy) ^F1	5,943	$0.00	$0.00
Grant/Award	Stock Option (Right to buy) ^F2	5,083	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to buy) — 11,026 contracts (Direct)

Footnotes (2)

F1. Subject to continued service, one-third of the shares underlying the stock option will vest on the first anniversary of the grant date, and the remaining shares underlying the stock option will vest in 24 substantially equal monthly installments thereafter.
F2. Represents options to purchase shares of the registrant's common stock in lieu of prorated director's cash compensation for 2026 pursuant to the Director's Compensation Plan effective August 15, 2026, granted under the Issuer's 2026 Omnibus Equity Incentive Plan. Subject to continued service, 100% of the stock options will vest on December 31, 2026.

Key Figures

Stock options granted: 5,943 options Stock options granted in lieu of cash compensation: 5,083 options Exercise price: $4.57 per share +4 more

7 metrics

Stock options granted 5,943 options Stock Option (Right to buy) granted to Peter Cicala on August 31, 2026

Stock options granted in lieu of cash compensation 5,083 options Options in lieu of prorated 2026 director cash compensation granted August 31, 2026

Exercise price $4.57 per share Exercise price for both option grants to purchase Ernexa Therapeutics Inc. common stock

Option expiration date August 31, 2036 Expiration date for both stock option grants to Peter Cicala

Cliff vesting portion One-third of 5,943 options Vests on the first anniversary of the August 31, 2026 grant date, subject to continued service

Remaining vesting schedule 24 monthly installments Remaining 5,943-option grant vests in 24 substantially equal monthly installments

Full vesting date for 5,083 options December 31, 2026 100% of the 5,083 stock options vest on this date, subject to continued service

Key Terms

Stock Option (Right to buy), vesting, Director's Compensation Plan, 2026 Omnibus Equity Incentive Plan, +1 more

5 terms

Stock Option (Right to buy) financial

"security_title: Stock Option (Right to buy)"

vesting financial

"shares underlying the stock option will vest on the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Director's Compensation Plan financial

"pursuant to the Director's Compensation Plan effective August 15, 2026"

2026 Omnibus Equity Incentive Plan financial

"granted under the Issuer's 2026 Omnibus Equity Incentive Plan"

prorated director's cash compensation financial

"in lieu of prorated director's cash compensation for 2026"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Peter Cicala receive from ERNA on August 31, 2026?

On August 31, 2026, Peter Cicala received two stock option grants from Ernexa Therapeutics Inc.: one for 5,943 options and another for 5,083 options, each to purchase common stock at an exercise price of $4.57 per share, expiring August 31, 2036.

What are the vesting terms for the 5,943 ERNA stock options granted to Peter Cicala?

For the 5,943 Ernexa Therapeutics Inc. options, one-third of the underlying shares vest on the first anniversary of the August 31, 2026 grant date. The remaining shares vest in 24 substantially equal monthly installments, subject to continued service.

How do the 5,083 ERNA stock options granted to Peter Cicala vest?

The 5,083 Ernexa Therapeutics Inc. stock options, issued in lieu of prorated 2026 director cash compensation under the Director's Compensation Plan, vest 100% on December 31, 2026, subject to continued service.

What is the exercise price and expiration date of Peter Cicala’s ERNA stock options?

Both stock option grants to Peter Cicala have an exercise price of $4.57 per share and an expiration date of August 31, 2036, giving him the right to purchase Ernexa Therapeutics Inc. common stock at that price until that date, subject to vesting.

Were Peter Cicala’s 5,083 ERNA stock options part of his cash compensation?

Yes. The 5,083 options were granted in lieu of prorated director's cash compensation for 2026 under the Director's Compensation Plan effective August 15, 2026, and were granted under Ernexa Therapeutics Inc.'s 2026 Omnibus Equity Incentive Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/01/2026 - 09:56 PM EDT Accepted by SEC EDGAR 09/01/2026 - 09:56 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cicala Peter

(Last)

(First)

(Middle)

C/O ERNEXA THERAPEUTICS INC.

1035 CAMBRIDGE STREET, SUITE 18A

(Street)

CAMBRIDGE

MASSACHUSETTS

02141

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ernexa Therapeutics Inc. [ ERNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to buy)	$4.57	08/31/2026		A		5,943		⁽¹⁾	08/31/2036	Common Stock	5,943	$0	5,943	D
Stock Option (Right to buy)	$4.57	08/31/2026		A		5,083		⁽²⁾	08/31/2036	Common Stock	5,083	$0	5,083	D

Explanation of Responses:

1. Subject to continued service, one-third of the shares underlying the stock option will vest on the first anniversary of the grant date, and the remaining shares underlying the stock option will vest in 24 substantially equal monthly installments thereafter.

2. Represents options to purchase shares of the registrant's common stock in lieu of prorated director's cash compensation for 2026 pursuant to the Director's Compensation Plan effective August 15, 2026, granted under the Issuer's 2026 Omnibus Equity Incentive Plan. Subject to continued service, 100% of the stock options will vest on December 31, 2026.

	/s/ Peter Cicala	09/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR